Pro Medicus H1 Profit, Revenue Climb

Pro Medicus reported H1 profit before tax of A$243.3 million versus A$73.27 million a year earlier, driven largely by a A$149.04 million fair value gain on financial assets; underlying PBT rose 29.7% to A$90.7 million from A$69.9 million. Revenue increased to A$128.94 million from A$100.79 million and net income was A$171.22 million (163.60c per share) versus A$51.75 million (49.44c), reflecting stronger contract income and higher interest income. The board declared a fully franked interim dividend of 32 cents per share payable March 20, underscoring cash returns to shareholders while noting a significant portion of the headline profit was non-operational fair-value movement.

Analysis

Market structure: Pro Medicus (PME.AX) is the clear near-term winner — revenue +28% H1 and underlying PBT +29.7% signal growing pricing power in radiology IT/SaaS; smaller legacy imaging vendors (equipment-first players) and on-premise PACS providers are the likely losers as hospitals shift to cloud-native workflow software. The result should reallocate market share toward high-margin software vendors over 12–36 months, tightening supply of premium SaaS capacity and supporting multiple expansion for high-growth names. Cross-asset: a re-rating reduces equity downside but raises sensitivity to AUD moves (revenues partly FX-exposed) and to interest-rate-driven markdowns of financial assets, with options vol likely to compress post-release and corporate credit spreads for PME negligible given strong cash flow.

Risk assessment: Key tail risks are reversal of the A$149m fair-value gain (market loss >A$80m would meaningfully cut EPS), a major contract loss or cybersecurity breach, and regulatory procurement delays in large health systems. Immediate (days) risk is post-dividend flow and profit-taking; short-term (weeks/months) risk is guidance updates and contract disclosures; long-term (years) risk is increased competition from global incumbents or margin pressure as sales mix shifts. Hidden dependencies include reliance on mark-to-market gains and interest income; catalysts that could accelerate upside are large multi-hospital deal announcements or upgraded FY guidance.

Trade implications: Direct play — establish a tactical 2–3% long position in PME.AX within 2 weeks to capture continued SaaS momentum, trimming at +25–35% or if FY underlying PBT growth <15% year/year. Options — implement a 3–6 month bull-call spread sized 1–2% of portfolio to cap premium (buy near-ATM, sell ~25% OTM) to play upside while limiting loss if fair-value gains reverse. Relative value — pair long PME.AX (2%) vs short GE HealthCare (GEHC, 1.5–2%) to express SaaS vs legacy-equipment secular divergence over 6–12 months.

Contrarian angles: The market may be overpaying for one-off mark-to-market gains; consensus could underweight the probability that future earnings revert if interest rates rise or financial assets are revalued down by >A$50–80m. Historical parallels: software names that reported large FV swings (marked by macro moves) frequently underperformed on reversion despite solid core growth (6–12 month drawdowns of 15–30%). If interim dividend yield compresses or management stops buybacks/dividends, expect rapid multiple contraction — set a hard exit if announced adjustments reduce cash EPS by >20%.

Key Decisions for Investors

• Establish a 2–3% long position in PME.AX within the next 2 weeks; target a 12-month horizon with profit-taking at +25–35% and a stop-loss if underlying PBT guidance implies <15% y/y growth or if material fair-value reversals exceed A$80m.
• Buy a 3–6 month bull-call spread on PME.AX sized 1–2% of portfolio (buy near-ATM calls, sell ~25% OTM) to capture upside while limiting premium exposure; exit at +30% trade P/L or immediately after FY guidance misses.
• Execute a pair trade: long PME.AX 2% vs short GE HealthCare (GEHC) 1.5–2% to express SaaS/workflow outperformance vs legacy equipment over 6–12 months; rebalance if spread widens >15% or narrows below 5%.
• Reduce relative exposure to legacy imaging/equipment names (e.g., trim GEHC/PHIA positions by 1–2%) and redeploy proceeds into high-margin imaging software (PME.AX or equivalent) given secular SaaS adoption; reassess after next quarter results.
• Monitor three triggers over the next 30–60 days: (1) management FY guidance and contract win disclosures, (2) any reversal in fair-value gains >A$50m, and (3) dividend sustainability commentary — cut PME.AX positions if two of three triggers are negative.